Detection method and application of enterokinase protein purity

Through high-performance liquid chromatography combined with specific conditions, the sensitivity and polymerization of enterokinase protein purity detection is solved, and high-precision enterokinase protein detection is achieved, which improves the safety and stability of the drug.

CN119064510AActive Publication Date: 2024-12-03BEIJING GENETECH PHARML

Patent Information

Application Number
CN202411426202.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-09-30
Filing Date
2024-10-12
Publication Date
2024-12-03
Estimated Expiration
2044-10-12

AI Technical Summary

Technical Problem

There is a lack of effective method for detecting enterokinase protein purity in the prior art, especially insensitive to the detection of extremely small and extremely large molecules, and protein polymerization may affect the results.

Method used

Using high performance liquid chromatography, using octadecylsilane bonded silica gel as filler, trifluoroacetic acid aqueous solution and trifluoroacetic acid acetonitrile solution as mobile phase, combined with specific gradient elution procedures and detection wavelength, the column gentle flow rate is set, Improve the isolation effect and detection precision of enterokinase protein.

Benefits of technology

It achieves high precision and good stability detection of enterokinase protein, shortens the detection time, and can quickly and comprehensively evaluate the purity of enterokinase, which helps to improve the safety and stability of the drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119064510A_ABST
    Figure CN119064510A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of drug detection, and provides a method for detecting the purity of enterokinase protein, which takes octadecylsilane chemically bonded silica as a filler, a trifluoroacetic acid aqueous solution as a mobile phase A and a trifluoroacetic acid acetonitrile solution as a mobile phase B, and adopts a specific elution procedure to detect the purity of the enterokinase protein. According to the method, the detection time is shortened, meanwhile, the separation effect of enterokinase protein components is improved, the separation degree is good, the method is simple, and the detection method is high in precision and good in stability and repeatability, so that the purity of enterokinase protein can be comprehensively and rapidly detected, quality control of enterokinase is facilitated, and the method is suitable for popularization and application. Therefore, the use safety and stability of the medicine can be improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of drug detection, and specifically to a method and application for detecting the purity of enterokinase protein. Background Art

[0002] Enterokinase is a heterodimeric serine protease present in the duodenum of mammals. At present, the method for detecting the purity of enterokinase protein is SDS-PAGE non-reducing electrophoresis, which can detect proteins of different molecular weights and evaluate the purity of proteins by observing whether the protein bands after electrophoresis are clear and single. This method has high resolution and simple operation, but it is not sensitive to extremely small and extremely large protein molecules, and proteins may aggregate during electrophoresis, thus affecting the final results. Summary of the invention

[0003] The problem to be solved by the present application is that there is no method disclosed in the prior art to effectively detect the purity of enterokinase protein; therefore, the present application provides a method for detecting the purity of enterokinase protein.

[0004] To this end, the present application provides a method for detecting the purity of enterokinase protein, comprising the following steps:

[0005] After the enterokinase sample to be tested is diluted into a sample solution, the sample solution is tested by high performance liquid chromatography;

[0006] The chromatographic conditions in the high performance liquid chromatography method include using octadecylsilane bonded silica gel as the filler, trifluoroacetic acid aqueous solution as the mobile phase A, and trifluoroacetic acid acetonitrile solution as the mobile phase B, and performing gradient elution as specified in the following table:

[0007]

[0008] In some optional embodiments, the volume concentration of trifluoroacetic acid in the trifluoroacetic acid aqueous solution is 0.08-0.12%; the volume concentration of trifluoroacetic acid in the trifluoroacetic acid acetonitrile solution is 0.08-0.12%;

[0009] Perform gradient elution as specified in the following table:

[0010]

[0011] In some optional embodiments, the detection wavelength is 214-280 nm, optionally, the detection wavelength is 214 nm.

[0012] In some optional embodiments, in the chromatographic conditions, the injection volume of the sample solution is 5-100 μL, and optionally, the injection volume of the sample solution is 100 μL.

[0013] In some optional embodiments, the column temperature is 30-65°C, optionally, the column temperature is 40°C;

[0014] And / or, the flow rate is 0.8-1.0 mL / min, optionally, the flow rate is 1.0 mL / min.

[0015] In some optional embodiments, in the chromatographic conditions, the size of the chromatographic column is 150 mm×4.6 mm, and the particle size of the filler is 5 μm.

[0016] In some optional embodiments, the method for preparing the sample solution is: measuring the enterokinase sample to be tested, and adding a solvent to prepare the sample solution;

[0017] Optionally, the ratio of the mass of the enterokinase sample to the volume of the solvent is 100-150:1; the relationship between mass and volume is μg / mL; and / or, the solvent is any one of glycerol aqueous solution, ultrapure water, trifluoroacetic acid aqueous solution, Tris aqueous solution, and a mixed solution of Tris aqueous solution and glycerol, and the volume concentration of glycerol in the glycerol aqueous solution is 40-60%.

[0018] In some optional embodiments, the detection method further comprises the step of using a glycerol aqueous solution as a reference solution and detecting the reference solution according to the high performance liquid chromatography method in the detection method to obtain a reference spectrum;

[0019] Optionally, the reference solution is a glycerol aqueous solution; the volume concentration of glycerol in the glycerol aqueous solution is 40-60%.

[0020] The technical solution of this application has the following advantages:

[0021] 1. The method for detecting the purity of enterokinase protein provided in the present application uses octadecylsilane bonded silica gel as a filler, trifluoroacetic acid aqueous solution as mobile phase A, trifluoroacetic acid acetonitrile solution as mobile phase B, and a specific elution procedure. While shortening the detection time, it also improves the separation effect of enterokinase protein components, has good separation, simple method, and high precision and good stability. Therefore, the purity of enterokinase protein can be comprehensively and quickly detected, which is beneficial to the quality control of enterokinase, thereby helping to improve the safety and stability of the use of the drug. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] In order to more clearly illustrate the specific implementation methods of the present application or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0023] Figure 1 is a comparison of the characteristic spectrum of the enterokinase sample and the characteristic spectrum of the reference substance in Example 1 of the present application;

[0024] Figure 2 is the chromatogram of the enterokinase sample in Example 1 of the present application;

[0025] Figure 3 is the chromatogram obtained after elution under the first gradient condition in Experimental Example 1 of the present application;

[0026] Figure 4 is the chromatogram obtained after elution under the second gradient condition in Experimental Example 1 of the present application;

[0027] Figure 5 is the chromatogram obtained after elution under the third gradient condition in Experimental Example 1 of the present application;

[0028] Figure 6 Chromatogram of the blank reference solution under the third gradient condition in Experimental Example 1 of the present application;

[0029] Figure 7 The chromatogram with a wavelength of 214 nm in Experimental Example 1 of the present application;

[0030] Figure 8 This is the chromatogram of Experimental Example 1 of the present application with a wavelength of 280 nm;

[0031] Fig. 9 This is the chromatogram of the column temperature of 40°C in Experimental Example 1 of the present application;

[0032] Fig.10 This is the chromatogram of the column temperature of 65°C in Experimental Example 1 of the present application;

[0033] Fig.11 It is the chromatogram detected by the chromatographic column ① in Experimental Example 1 of the present application;

[0034] Fig.12 It is the chromatogram detected by chromatographic column ② in Experimental Example 1 of the present application;

[0035] Fig.13 It is the chromatogram detected by chromatographic column ③ in Experimental Example 1 of the present application;

[0036] Fig.14 It is the chromatogram detected by chromatographic column ④ in Experimental Example 1 of the present application;

[0037] Fig.15 This is the chromatogram of the enterokinase sample diluted to 1.5 μg / ml in Experimental Example 1 of the present application;

[0038] Fig.16 This is the chromatogram of the enterokinase sample diluted to 1.2 μg / ml in Experimental Example 1 of the present application;

[0039] Fig.17 This is the chromatogram of the enterokinase sample diluted to 1.0 μg / ml in Experimental Example 1 of the present application.

[0040] The ordinate in the above chromatogram is absorbance (AU) and the abscissa is time (minutes). DETAILED DESCRIPTION

[0041] The following examples are provided to further understand the present application better, are not limited to the best mode, are not limited to the content and protection scope of the present application, and any product identical or similar to the present application obtained by combining the features of the present application with other prior arts under the enlightenment of the present application, all falls within the protection scope of the present application. The specific experimental steps or conditions not indicated in the examples can be carried out according to the operation or conditions of the conventional experimental steps described in the documents in this area. The reagents used or the instruments not indicated by the manufacturer are all conventional reagent products that can be obtained by commercial purchase, and the percentages not indicated in the present application are all volume percentages.

[0042] The instruments and reagents used in this application are as follows:

[0043] 1. Instruments and test drugs

[0044] 1.1 Instrument

[0045] Chromatograph: Photodiode array detector (PDA detector);

[0046] Chromatographic column: ① Waters Symmetry 300TM-C18, 4.6*150mm, 5μm;

[0047] ②Waters XBridge C18, 5μm, 4.6*250nm,

[0048] ③Agilent Zorbax SB-C3, 44.6*150mm, 5μm;

[0049] ④Zorbax Eclipse XDB-C18, 4.6*250mm, 5μm.

[0050] 1.2 Drug testing

[0051] Glycerol (Batch No.: 20221207, purchased from Sinopharm Chemical Reagent Co., Ltd.)

[0052] Enterokinase sample (Batch No.: 20201219, purchased from Chengdu Yuangu Biotechnology Co., Ltd.);

[0053] 1.3 Reagents

[0054] Trifluoroacetic acid and acetonitrile were of chromatographic grade (Thermo Fisher, Merck), and water was ultrapure water; other reagents were of analytical grade.

[0055] Example 1

[0056] A method for detecting the purity of enterokinase protein, comprising:

[0057] (1) Preparation of enterokinase sample solution: Accurately measure an appropriate amount of enterokinase sample, add 50% glycerol aqueous solution to make the enterokinase sample concentration 120-150 μg / ml, and stir evenly to obtain the solution.

[0058] The enterokinase sample in this example was purchased from Chengdu Yuangu Biotechnology Co., Ltd., batch number: 20201219.

[0059] (2) Preparation of reference solution: Take a 50% volume concentration of glycerol aqueous solution as the blank reference solution.

[0060] (3) High performance liquid chromatography detection

[0061] The enterokinase solution and the reference solution were tested by high performance liquid chromatography. The chromatographic conditions were as follows: Column: Symmetry 300 TM C18 5μm, 4.6×150mm; octadecylsilane bonded silica gel as filler; 0.1% trifluoroacetic acid aqueous solution as mobile phase A, 0.1% trifluoroacetic acid acetonitrile solution as mobile phase B, gradient elution according to the provisions in Table 1; detection wavelength 214nm; flow rate 1.0ml / min, column temperature 40℃, injection volume 100μl, sample chamber temperature 10℃; recording time: 76min; (delay injection 5min). The number of theoretical plates calculated based on the main peak of enterokinase protein should not be less than 10,000.

[0062] Table 1 Gradient elution program

[0063]

[0064] The blank reference solution is tested according to the above-mentioned high performance liquid chromatography to obtain a reference characteristic spectrum, and the enterokinase sample is tested according to the above-mentioned high performance liquid chromatography to obtain an enterokinase sample characteristic spectrum; the characteristic spectrum of the enterokinase sample is compared with the characteristic spectrum of the reference, such as Figure 1 As shown in FIG. 1 , the retention time of enterokinase is 40.6 min. The enterokinase sample is detected by the above-mentioned high performance liquid chromatography to obtain the characteristic spectrum of the enterokinase sample as shown in FIG. Figure 2The results showed that the chromatographic peak purity of enterokinase was good, among which the chromatographic peak of enterokinase was peak 5, the retention time of enterokinase was 40.6min, the separation degree between enterokinase and adjacent peaks was 14.49, and the theoretical plate number was above 28800.

[0065] After the enterokinase sample is tested by HPLC, the chromatographic peak area of ​​enterokinase in the test solution is calculated, and the sum of the areas of the various chromatographic peaks in the test solution is calculated to obtain the total chromatographic peak area. Then, the chromatographic peak area of ​​enterokinase is divided by the total chromatographic peak area to obtain the percentage of the chromatographic peak area of ​​enterokinase to the total chromatographic peak area, which is the purity of enterokinase in the test sample. The purity of enterokinase in the enterokinase sample in this embodiment is 97.48%.

[0066] The above description shows that the detection method in this embodiment can effectively obtain a characteristic spectrum with good separation of enterokinase. The detection method of the present application can comprehensively and quickly detect the purity of enterokinase protein, which is beneficial to the quality control of enterokinase, thereby helping to improve the safety and stability of the drug.

[0067] Test Example 1

[0068] 1. Establishment of chromatographic conditions

[0069] Preparation of sample solution: Accurately measure an appropriate amount of enterokinase sample, add 50% by volume glycerol aqueous solution to make its concentration 120 μg / ml, stir evenly, and use this as the sample solution.

[0070] Preparation of reference solution: Take a glycerol aqueous solution with a volume concentration of 50% as the blank reference solution.

[0071] The sample solutions and reference solutions in the following experiments were prepared according to this procedure.

[0072] 1.1 Selection of elution gradient and flow rate

[0073] The sample solution was tested by high performance liquid chromatography, and the chromatographic conditions were as follows: the chromatographic column was Symmetry 300 TM C18 5μm, 4.6×150mm; octadecylsilane bonded silica gel as filler; 0.1% trifluoroacetic acid aqueous solution as mobile phase A, 0.1% trifluoroacetic acid acetonitrile solution as mobile phase B, gradient elution according to the gradient and flow rate specified in Table 3 or Table 4 or Table 5; column temperature 40°C, injection volume 100μl, detection wavelength 214nm; sample chamber temperature 10°C.

[0074] Table 3 First gradient elution conditions

[0075]

[0076] Table 4 Second gradient elution conditions

[0077] Time (min) Mobile phase A (Vol%) Mobile phase B (Vol%) Flow rate (ml / min) 0 100 0 0.8 5 75 25 0.8 20 40 60 0.8 25 20 80 0.8 30 100 0 0.8 35 100 0 0.8

[0078] Table 5 The third gradient elution conditions

[0079] Time (minutes) Mobile phase Mobile phase B (Vol%) Flow rate (ml / min) 0~70 100 0→70 1.0 70~75 30→ 70→100 1.0 75~76 0→1 100→0 1.0

[0080] The chromatogram obtained after elution under the first gradient condition in Table 3 is shown in FIG. Figure 3 The chromatogram obtained after elution under the second gradient condition in Table 4 is shown in Figure 4 The chromatogram obtained after elution under the third gradient condition in Table 5 is shown in Figure 5 and Table 6.

[0081] According to the first gradient of Table 3, the chromatogram shows that the baseline fluctuates greatly, and the retention time of the main peak is close to the retention time of the impurities introduced by the blank. Therefore, the gradient is slowed down, and the elution is performed according to the second gradient elution conditions of Table 4. The results show that the baseline is uneven. The inventor lengthened the gradient and increased the flow rate to optimize the baseline fluctuation, and eluted according to the elution conditions of Table 5.

[0082] At the same time, the blank reference solution was tested using the above chromatographic conditions under the gradient conditions in Table 5. The chromatogram is shown in Figure 6 .

[0083] from Figure 3-6 The chromatograms in the figure were compared and the results showed Figure 5 The chromatographic peaks are rich in information, the separation effect of the enterokinase protein chromatographic peak is good and the response is high, so this gradient condition was selected for subsequent research.

[0084] Table 6 System suitability parameters for elution under three different gradient conditions

[0085]

[0086] 1.2 Selection of detection wavelength

[0087] The sample solution was tested by high performance liquid chromatography, and the chromatographic conditions were as follows: the chromatographic column was Symmetry 300 TM C18 5μm, 4.6×150mm; octadecylsilane bonded silica gel as filler; 0.1% trifluoroacetic acid aqueous solution as mobile phase A, 0.1% trifluoroacetic acid acetonitrile solution as mobile phase B, gradient elution according to the provisions in Table 1; flow rate 1.0ml / min, column temperature 40℃, injection volume 100μl, sample chamber temperature 10℃; recording time: 76min; (delay injection 5min). Detection wavelength is 214nm or 280nm. The chromatogram with a wavelength of 214nm is as follows Figure 7 As shown, the chromatogram with a wavelength of 280nm is as follows Figure 8 The comparison results between the two are shown in Table 7.

[0088] The test results show that the peak height of the chromatographic peak at a wavelength of 214 nm is about 17 times higher than that of the chromatographic peak at a wavelength of 280 nm. The sensitivity is higher at a wavelength of 214 nm, so 214 nm was selected as the detection wavelength for subsequent research.

[0089] Table 7 System adaptability parameters at different detection wavelengths

[0090]

[0091]

[0092] 1.3 Selection of different column temperatures

[0093] The effects of different column temperatures on the characteristic spectrum of enterokinase were compared. The column temperature was set at 40°C or 65°C. The sample solution was tested by high performance liquid chromatography. The chromatographic conditions were as follows: the chromatographic column was Symmetry 300 TM C18 5μm, 4.6×150mm; octadecylsilane bonded silica gel as filler; 0.1% trifluoroacetic acid aqueous solution as mobile phase A, 0.1% trifluoroacetic acid acetonitrile solution as mobile phase B, gradient elution according to the provisions in Table 3; flow rate 1.0ml / min, injection volume 100μl, detection wavelength 214nm; sample chamber temperature 10℃. According to the above method, the determination was carried out to observe the effect of different column temperatures on the separation effect of enterokinase protein.

[0094] The chromatogram at a column temperature of 40°C is Fig. 9 The chromatogram of enterokinase with a retention time of 16.637 min and a column temperature of 65 °C is as follows: Fig.10 , the retention time of enterokinase was 16.251min. The results showed that under different temperature conditions, the relative position of the impurity peak and the main peak could be observed. After increasing the column temperature, the retention time of the main peak was about 0.4min, which did not change the data results and peak shape much, so the column temperature of 40℃ was selected for subsequent research.

[0095] 1.4 Selection of different chromatographic columns

[0096] Enterokinase solution was measured using different brands of octadecylsilane bonded silica gel columns (column ①: Waters Symmetry 300TM-C18, 4.6*150mm, 5μm; column ②: Waters XBridge C18, 5μm, 4.6*250nm, column ③: Agilent Zorbax SB-C3, 44.6*150mm, 5μm; column ④: Zorbax Eclipse XDB-C18, 4.6*250mm, 5μm). The chromatographic column was Symmetry 300TM-C18 5μm, 4.6×150mm; octadecylsilane bonded silica gel as filler; 0.1% trifluoroacetic acid aqueous solution as mobile phase A, 0.1% trifluoroacetic acid acetonitrile solution as mobile phase B, gradient elution according to the provisions in Table 5; flow rate 1.0ml / min, injection volume 100μl, detection wavelength 214nm; column temperature 40℃; sample chamber temperature 10℃; recording time: 76min (delayed injection 5min). The results are as follows Figure 11-14 and Table 8; Fig.11 This is the chromatogram detected by chromatographic column ①; Fig.12 This is the chromatogram detected by chromatographic column ②; Fig.13 This is the chromatogram detected by chromatographic column ③; Fig.14 This is the chromatogram detected by chromatographic column ④.

[0097] The results show that by comparing the characteristic spectra measured by different brands of chromatographic columns, it can be found that the baselines of the chromatograms of chromatographic columns ②, ③ and ④ all drift to varying degrees, and the baseline of the chromatogram of chromatographic column ③ even fluctuates cliff-like at 23.4 minutes, and chromatographic column ④ does not elute the peak except enterokinase protein. Therefore, the preferred chromatographic column is Symmetry C18, 4.6*150mm, 5μm column.

[0098] Table 8 System suitability parameters for different chromatographic columns

[0099] Different columns Retention time area high Separation Tailing Factor Theoretical plate number Chromatographic column① 46.665 12487519 515515 28.58 1.07 28490.65 Chromatographic column② 31.198 2052118 61549 —— 0.99 20193.28 Chromatographic column ③ 29.486 8516523 168793 —— 1.52 8561.363 Chromatographic column ④ —— —— —— —— —— ——

[0100] 1.5 Determination of chromatographic conditions

[0101] Through the above test, it is determined that the chromatographic conditions of the present application are: the chromatographic column is Symmetry C18, 4.6*150mm, 5μm chromatographic column; octadecylsilane bonded silica gel is used as filler; 0.1% trifluoroacetic acid aqueous solution by volume concentration is used as mobile phase A, 0.1% trifluoroacetic acid acetonitrile solution by volume concentration is used as mobile phase B, and gradient elution is performed according to the provisions in Table 5; the flow rate is 1.0ml / min, the injection volume is 100μl, and the detection wavelength is 214nm; the column temperature is 40℃; the sample chamber temperature is 10℃; the recording time is 76min (delayed injection 5min)

[0102] Test Example 2 Determination of detection limit

[0103] The enterokinase samples were tested according to the chromatographic conditions determined in 1.5 of Experimental Example 1. The enterokinase samples were diluted to 1.5 μg / ml, 1.2 μg / ml, and 1.0 μg / ml for testing. The results are as follows: Figure 15-17 and as shown in Table 9.

[0104] Table 9 Detection of enterokinase samples with different concentrations

[0105]

[0106] According to the test results, the signal-to-noise ratio was 5.52 at 1.5 μg / ml, the signal-to-noise ratio was 4.70 at 1.2 μg / ml, and 1.0 μg / ml was not detected, so the detection limit of the detection method of the present application was 1.2 μg / ml.

[0107] Test Example 3

[0108] 1. Instrument precision

[0109] The enterokinase sample was tested according to the chromatographic conditions determined in 1.5 of Experimental Example 1, and the enterokinase sample was diluted to 150 μg / ml with the control solution, and 6 portions were prepared in parallel, and the tests were performed separately to complete the repeatability experiment. On another day, another experimenter used another device to test the enterokinase sample according to the chromatographic conditions determined in 1.5 of Experimental Example 1, and the enterokinase sample was diluted to 120 μg / ml with the control solution, and 6 portions were prepared in parallel, and the tests were performed separately to complete the intermediate precision test. The experimental results are shown in Table 10 below:

[0110] Table 10 Precision test results

[0111]

[0112] The results showed that the method had good precision.

[0113] 2. Durability

[0114] The detection of the enterokinase sample according to the chromatographic conditions determined in 1.5 of Experimental Example 1 is regarded as the standard conditions, wherein the column temperature changes by 40°C±2°C and the flow rate changes by 1.0ml / min±0.1ml / min, respectively, are regarded as the changed conditions. The enterokinase sample is diluted to 120-150μg / ml with the control solution and detected according to the chromatographic conditions, respectively. The experimental results are shown in Table 11:

[0115] Table 11 Durability test results

[0116]

[0117]

[0118] It can be seen from the above table that the detection method of the present application has good durability.

[0119] The above experiments show that the method for detecting the protein purity of enterokinase and its pharmaceutical preparation provided in the present application uses octadecylsilane bonded silica gel as a filler, trifluoroacetic acid aqueous solution as mobile phase A, trifluoroacetic acid acetonitrile solution as mobile phase B, and a specific elution procedure. While shortening the detection time, it also improves the separation effect of enterokinase protein components, has good separation, simple method, and high precision, stability and repeatability. Therefore, the purity and content of enterokinase protein can be comprehensively and quickly detected, which is beneficial to the quality control of enterokinase, thereby helping to improve the safety and stability of the use of the drug.

[0120] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection created by this application.

Claims

1. A method for detecting the purity of enterokinase protein, characterized in that: The steps include: After the enterokinase sample to be tested is diluted into a sample solution, the sample solution is tested by high performance liquid chromatography; The chromatographic conditions in the high performance liquid chromatography method include using octadecylsilane bonded silica gel as the filler, trifluoroacetic acid aqueous solution as the mobile phase A, and trifluoroacetic acid acetonitrile solution as the mobile phase B, and performing gradient elution as specified in the following table:

2. The method for detecting the purity of enterokinase protein according to claim 1, characterized in that: The volume concentration of trifluoroacetic acid in the trifluoroacetic acid aqueous solution is 0.08-0.12%; the volume concentration of trifluoroacetic acid in the trifluoroacetic acid acetonitrile solution is 0.08-0.12%; Perform gradient elution as specified in the following table:

3. The method for detecting the purity of enterokinase protein according to claim 1 or 2, characterized in that: The detection wavelength is 214-280 nm, optionally, the detection wavelength is 214 nm.

4. The method for detecting the purity of enterokinase protein according to claim 1 or 2, characterized in that: In the chromatographic conditions, the injection volume of the sample solution is 5-100 μL, and optionally, the injection volume of the sample solution is 100 μL.

5. The method for detecting the purity of enterokinase protein according to claim 1 or 2, characterized in that: The column temperature is 30-65°C, optionally, the column temperature is 40°C; And / or, the flow rate is 0.8-1.0 mL / min, optionally, the flow rate is 1.0 mL / min.

6. The method for detecting the purity of enterokinase protein according to claim 1 or 2, characterized in that: In the chromatographic conditions, the size of the chromatographic column is 150 mm×4.6 mm, and the particle size of the filler is 5 μm.

7. The method for detecting the purity of enterokinase protein according to claim 1 or 2, characterized in that: The method for preparing the sample solution is as follows: measuring the enterokinase sample to be tested, and adding a solvent to prepare the sample solution; Optionally, the ratio of the mass of the enterokinase sample to the volume of the solvent is 100-150:1; the relationship between mass and volume is μg / mL; and / or, the solvent is any one of a glycerol aqueous solution, ultrapure water, a trifluoroacetic acid aqueous solution, a Tris aqueous solution, and a mixed solution of a Tris aqueous solution and glycerol, the volume concentration of glycerol in the glycerol aqueous solution is 40-60%, and the final concentration of Tris in the Tris aqueous solution is 20 mmol / L.

8. The method for detecting the purity of enterokinase protein according to any one of claims 1 to 7, characterized in that: The detection method further comprises the step of using a glycerol aqueous solution as a reference solution and detecting the reference solution by high performance liquid chromatography according to any one of the detection methods of claims 1 to 7 to obtain a reference spectrum; Optionally, the volume concentration of glycerol in the glycerol aqueous solution is 40-60%.

Citation Information

Patent Citations

  • Method for preparing medicinal recombinant human interleukin-11

    CN101892279A

  • Purification method of high-purity recombinant enterokinase

    CN116716279A

  • Method for preparing parathormone 1-34

    CN1916172A

  • Synthetic Gene for Enhanced Expression in E. Coli

    US20090035815A1

Cited By

  • Reversed phase chromatographic analysis method for enterokinase protein purity

    CN122084779A